Access and Evidence
Pragmatic Trials: RWE’s Hidden Gem
Pragmatic trials continue to be overlooked in the RWE space – particularly in the US. Can we expect to see wider stateside adoption?
More Articles
Commercial
The Big Trends Transforming Pharma
The industry is fast approaching a promising new future. How is it getting there?
Patients and Medical
The Power Of Empathy
In a bid to better understand and engage patients, pharma companies are becoming as compassionate as they are scientific.
Commercial
Artificial Intelligence: The Counter-Argument
AI is being touted as the doctor’s new lifeline — we put this proposition to a skeptical doctor.
Commercial
Sizing Up Pharma’s Tech Maturity
Amateurs or aficionados? We get an expert appraisal of the industry’s tech proficiency
Access and Evidence
The Naked Truth About Outcomes-Based Pricing
Hype around outcomes-based contracts has been doing the rounds for some time now, but is pharma delivering the goods?
Patients and Medical
Pharma, Stop Flummoxing Patients
Efforts to empower patients are undermined by bamboozling medical information. Is there a straight-forward solution?
Commercial
Leadership In Japan
In the face of new drug pricing reforms, the need to nurture strong leadership is imperative, but not without its challenges.
Commercial
How To Attract Investors
The precarious climate in the US might have spooked some pharma investors – but others are looking to targeted therapies to get more bang for their buck.
Commercial
How Well Do You Know Your HCP?
Machine learning is a boon for customer engagement. How can pharma best use it?